ZIOPHARM Oncology Inc.  

(Public, NASDAQ:ZIOP)   Watch this stock  
Find more results for ZIOP
3.66
-0.14 (-3.68%)
After Hours: 3.66 0.00 (0.00%)
Apr 23, 5:09PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.50 - 3.84
52 week 1.55 - 5.58
Open 3.82
Vol / Avg. 0.00/1.41M
Mkt cap 368.04M
P/E     -
Div/yield     -
EPS -0.67
Shares 100.56M
Beta 2.40
Inst. own 54%
May 6, 2014
ZIOPHARM ONCOLOGY INC at Mizuho Securities USA Healthcare Corporate Access Day Add to calendar
May 5, 2014
Q1 2014 ZIOPHARM ONCOLOGY INC Earnings Release (Estimated) Add to calendar
Mar 28, 2014
ZIOPHARM ONCOLOGY INC at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference
Mar 3, 2014
Q4 2013 ZIOPHARM ONCOLOGY INC Earnings Release
Feb 10, 2014
ZIOPHARM ONCOLOGY INC at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -4452.00% -7138.38%
Operating margin -3360.50% -7214.12%
EBITD margin - -7121.88%
Return on average assets -70.56% -73.61%
Return on average equity -134.73% -116.75%
Employees 43 -
CDP Score - -

Address

Parris Building, #34, 1 First Avenue
BOSTON, MA 02129
United States - Map
+1-617-2591970 (Phone)
+1-617-2412855 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ZIOPHARM Oncology, Inc., is a biotechnology company. The Company employs gene expression and control technology to deliver deoxyribonucleic acid (DNA) for the treatment of cancer. The Company's technology employs Intrexon Corporation's RheoSwitch Therapeutic System to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. As of October 18, 2013, the technology was being evaluated in Phase II clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company is also developing small molecules as potential cancer therapeutics.

Officers and directors

Jonathan J. Lewis MD PhD Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Kevin G. Lafond Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 57
Bio & Compensation  - Reuters
Caesar J. Belbel Executive Vice President, Chief Legal Officer, Secretary
Age: 53
Bio & Compensation  - Reuters
Murray F. Brennan M.D. Non-Executive Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
Randal J. Kirk Director
Age: 59
Bio & Compensation  - Reuters
James A. Cannon Independent Director
Age: 74
Bio & Compensation  - Reuters
Wyche Jr Fowler Jr., J.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Timothy McInerney Independent Director
Age: 52
Bio & Compensation  - Reuters